These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 20415260)

  • 21. Cross clade prophylactic and therapeutic efficacy of polyvalent equine immunoglobulin F(ab')2 against highly pathogenic avian influenza H5N1 in mice.
    Zhao Z; Yan F; Chen Z; Luo D; Duan Y; Yang P; Li Z; Peng D; Liu X; Wang X
    Int Immunopharmacol; 2011 Dec; 11(12):2000-6. PubMed ID: 21906698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
    Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
    Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus.
    Lu X; Liu F; Zeng H; Sheu T; Achenbach JE; Veguilla V; Gubareva LV; Garten R; Smith C; Yang H; Stevens J; Xu X; Katz JM; Tumpey TM
    Virology; 2014 Apr; 454-455():169-75. PubMed ID: 24725943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental study of the efficiency of oxidized dextran for prevention of influenza A/H5N1.
    Shkurupy VA; Potapova OV; Sharkova TV; Troitskii AV; Gulyaeva EP; Bystrova TN; Shestopalov AM
    Bull Exp Biol Med; 2014 Nov; 158(1):112-4. PubMed ID: 25403410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.
    Hoelscher MA; Garg S; Bangari DS; Belser JA; Lu X; Stephenson I; Bright RA; Katz JM; Mittal SK; Sambhara S
    Lancet; 2006 Feb; 367(9509):475-81. PubMed ID: 16473124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antisense oligonucleotides targeting the RNA binding region of the NP gene inhibit replication of highly pathogenic avian influenza virus H5N1.
    Zhang T; Wang TC; Zhao PS; Liang M; Gao YW; Yang ST; Qin C; Wang CY; Xia XZ
    Int Immunopharmacol; 2011 Dec; 11(12):2057-61. PubMed ID: 21933722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model.
    Boltz DA; Rehg JE; McClaren J; Webster RG; Govorkova EA
    J Infect Dis; 2008 May; 197(9):1315-23. PubMed ID: 18422444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
    Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
    Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H
    Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Epidemiology, clinical picture, prevention and treatment of Avian influenza].
    Angelava NA; Angelava AV
    Georgian Med News; 2006 Feb; (131):69-76. PubMed ID: 16575138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection from pulmonary tissue damage associated with infection of cynomolgus macaques by highly pathogenic avian influenza virus (H5N1) by low dose natural human IFN-α administered to the buccal mucosa.
    Strayer DR; Carter WA; Stouch BC; Stittelaar KJ; Thoolen RJ; Osterhaus AD; Mitchell WM
    Antiviral Res; 2014 Oct; 110():175-80. PubMed ID: 25111905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.
    Sandbulte MR; Jimenez GS; Boon AC; Smith LR; Treanor JJ; Webby RJ
    PLoS Med; 2007 Feb; 4(2):e59. PubMed ID: 17298168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice.
    Szretter KJ; Gangappa S; Lu X; Smith C; Shieh WJ; Zaki SR; Sambhara S; Tumpey TM; Katz JM
    J Virol; 2007 Mar; 81(6):2736-44. PubMed ID: 17182684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
    Ninomiya A; Imai M; Tashiro M; Odagiri T
    Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Study of antiviral activity of extracts obtained from basidial fungi against influenza viruses of different subtypes in experiments in vitro and in vivo].
    Kabanov AS; Kosogova TA; Shishkina LN; Tepliakova TV; Skarnovich MO; Mazurkova NA; Puchkova LI; Malkova EM; Stavskiĭ EA; Drozdov IG
    Zh Mikrobiol Epidemiol Immunobiol; 2011; (1):40-3. PubMed ID: 21449077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studying the pathogenicity of avian influenza virus subtype H5N1 strains from the Russian Federation using mouse model.
    Shestopalov AM; Sharshov KA; Zaykovskaya AV; Rassadkin YN; Drozdov IG; Shkurupy VA; Potapova OV; Luzgina NG
    Bull Exp Biol Med; 2008 Sep; 146(3):341-3. PubMed ID: 19240855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DAS181 and H5N1 virus infection.
    Zhang H
    J Infect Dis; 2009 Apr; 199(8):1250, author reply 1250-1. PubMed ID: 19302014
    [No Abstract]   [Full Text] [Related]  

  • 39. Cell penetrable human scFv specific to middle domain of matrix protein-1 protects mice from lethal influenza.
    Dong-din-on F; Songserm T; Pissawong T; Srimanote P; Thanongsaksrikul J; Thueng-in K; Moonjit P; Lertwatcharasarakul P; Seesuay W; Chaicumpa W
    Viruses; 2015 Jan; 7(1):154-79. PubMed ID: 25594836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preventive Effects of Oxidized Dextran on Functional Activity of Pulmonary Macrophages in Mice Infected with Influenza A Virus.
    Potapova OV; Cherdantseva LA; Kovner AV; Sharkova TV; Troitskii AV; Shestopalov AM; Shkurupy VA
    Bull Exp Biol Med; 2018 May; 165(1):57-60. PubMed ID: 29796811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.